ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARQT vs LEGN // NET PROFIT MARGIN

Arcutis Biotherapeutics Inc. (NASDAQ) VS. Legend Biotech Corporation (NASDAQ) • 15-METRIC TALLY: ARQT 4 — LEGN 7
▲ NET PROFIT MARGIN LEADER: LEGN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. LEGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARQT LEGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 90.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -3.00% 9.90% -12.90 LEGN /roic <GO>
EV/EBITDA & P/E Valuation — 21.0x — TIE /valuation <GO>
Free Cash Flow Yield -0.16% 2.21% -2.37 LEGN /fcf-yield <GO>
Operating Margin -3.30% 13.90% -17.20 LEGN /operating-margins <GO>
Net Profit Margin ACTIVE -4.30% 10.90% -15.20 LEGN /net-margins <GO>
Revenue Growth (YoY) 91.30% 9.90% +81.40 ARQT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 7.78 3.74 +4.04 ARQT /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 LEGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 66.0 59.2 +6.80 ARQT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.00 1.04 -0.04 LEGN /macro-sensitivity <GO>
Forward P/E Multiple 24.0x 30.5x -6.50 ARQT /forward-pe <GO>
Enterprise Scale & Market Cap $4.03B $4.21B -$175.8M LEGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARQT REV LEGN REV ARQT GROSS % LEGN GROSS % ARQT FCF LEGN FCF
FY 2025 $376.1M — 90.2% — -$6.3M —
FY 2024 $196.5M — 90.3% — -$112.3M —
FY 2023 $59.6M — — — -$249.7M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
LEGN // BETA 1.04